Clinical trials: Esophageal Neoplasms
Eosinophilic Esophagitis (EoE)
BURDEN OF ESOPHAGEAL CANCER IN EOSINOPHILIC ESOPHAGITIS (ESCAPE STUDY)
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus that can lead to symptoms such as dysphagia and food impaction.
- Trial name
- ESCAPE (NCT07102329)
- Where
- Italy
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Gastric (Stomach) Cancer, Esophageal Cancer
A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies
An increasing body of evidence suggests that nutritional status is a key factor in determining the quality of life of cancer patients.
- Trial name
- NCT06997302
- Testing
- Nutritional Supplement
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
Perioperative Management and Outcomes of Minimally Invasive Esophagectomy
The investigators retrospectively reviewed the data of all patients who had undergone esophagectomy and reconstruction in 2015. Patient characteristics, the surgery performed, method of anesthesia, postoperative hospitalization…
- Trial name
- NCT03378869
- Testing
- esophagectomy
- Where
- Taiwan
- Volunteers
- 64 people
- Sponsor
- National Taiwan University Hospital
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.
- Trial name
- NCT06247956
- Testing
- SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection, Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
- Trial name
- DL-ESCC (NCT07088354)
- Testing
- The high-throughput extraction of large amounts of quantitative image features from medical images
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Esophageal Cancer, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002951
- Testing
- fluorouracil, hydroxyurea, surgical procedure
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Esophageal Neoplasms
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
To determine the activity and efficacy of the schema specified as dose regimen To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
- Trial name
- NCT00259402
- Testing
- Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Sanofi
Esophagitis
Risk of Cancer Among Pantoprazole Users
The primary objective is to assess whether the risk of gastric cancer is increased in pantoprazole users compared to users of other proton pump inhibitors.
- Trial name
- NCT01322633
- Testing
- Does not apply
- Volunteers
- 61,864 people
- Sponsor
- Pfizer
Barrett's Esophagus
The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus
Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.
- Trial name
- NCT01905202
- Testing
- Secretrol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Effexus Pharmaceutical
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Breast Carcinoma, Esophageal Carcinoma
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself.
- Conditions
- Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT00991094
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Gastric Cancer
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
Cancer of the food pipe (oesophagus) and stomach are increasingly common. Currently, most patients with cancer of the oesophagus and stomach are treated with surgery with or without additional chemotherapy or radiotherapy.
- Trial name
- SARONG-II (NCT06115629)
- Testing
- Surveillance protocol
- Where
- 13 sites in Germany, Ireland and 3 more
- Volunteers
- 952 people
- Sponsor
- University of Dublin, Trinity College
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival
In Siewert type II adenocarcinoma, the relationship between adenocarcinoma sub types and survival, histologic/biologic patterns related to the presence/absence of gastric greater curvature metastases, were investigated.
- Trial name
- SiewertIIEAC (NCT03416101)
- Testing
- Total Gastrectomy
- Where
- 2 sites in Italy
- Volunteers
- 154 people
- Sponsor
- University of Bologna
Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma
Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma
Esophageal cancers are the seventh most common cancer in the world and one of the most common causes of cancer deaths. In some parts of China, the incidence of SCC is among the highest in the world.
- Trial name
- NCT03900871
- Testing
- Acetylsalicylic acid
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Hebei Medical University Fourth Hospital
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Esophageal Cancer
A Comparison Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy
Surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high.
- Trial name
- NCT04217239
- Testing
- MIE Ivor- Lewis, MIE McKeown
- Where
- China
- Volunteers
- 272 people
- Sponsor
- The Second Hospital of Shandong University
Colorectal Cancer, Esophageal Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
- Trial name
- NCT05415475
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Esophageal Cancer
Assessment of Minimally Invasive Surgery for Esophageal Cancer
Evaluate the feasibility and outcome of minimally invasive management of esophageal cancer regarding 1. Surgical technique: A totally minimally invasive technique (combined thoracoscopic and laparoscopic approaches) for…
- Trial name
- NCT05662644
- Testing
- Minimally Invasive Surgery for Esophageal Cancer
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.